These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 14742190)

  • 1. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.
    Jacobson JM; Israel RJ; Lowy I; Ostrow NA; Vassilatos LS; Barish M; Tran DN; Sullivan BM; Ketas TJ; O'Neill TJ; Nagashima KA; Huang W; Petropoulos CJ; Moore JP; Maddon PJ; Olson WC
    Antimicrob Agents Chemother; 2004 Feb; 48(2):423-9. PubMed ID: 14742190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults.
    Jacobson JM; Lowy I; Fletcher CV; O'Neill TJ; Tran DN; Ketas TJ; Trkola A; Klotman ME; Maddon PJ; Olson WC; Israel RJ
    J Infect Dis; 2000 Jul; 182(1):326-9. PubMed ID: 10882617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults.
    Jacobson JM; Kuritzkes DR; Godofsky E; DeJesus E; Larson JA; Weinheimer SP; Lewis ST
    Antimicrob Agents Chemother; 2009 Feb; 53(2):450-7. PubMed ID: 19015347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team.
    Shearer WT; Israel RJ; Starr S; Fletcher CV; Wara D; Rathore M; Church J; DeVille J; Fenton T; Graham B; Samson P; Staprans S; McNamara J; Moye J; Maddon PJ; Olson WC
    J Infect Dis; 2000 Dec; 182(6):1774-9. PubMed ID: 11069253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.
    Jacobson JM; Saag MS; Thompson MA; Fischl MA; Liporace R; Reichman RC; Redfield RR; Fichtenbaum CJ; Zingman BS; Patel MC; Murga JD; Pemrick SM; D'Ambrosio P; Michael M; Kroger H; Ly H; Rotshteyn Y; Buice R; Morris SA; Stavola JJ; Maddon PJ; Kremer AB; Olson WC
    J Infect Dis; 2008 Nov; 198(9):1345-52. PubMed ID: 18771406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects.
    Hanna GJ; Lalezari J; Hellinger JA; Wohl DA; Nettles R; Persson A; Krystal M; Lin P; Colonno R; Grasela DM
    Antimicrob Agents Chemother; 2011 Feb; 55(2):722-8. PubMed ID: 21078951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus.
    Uckun FM; Bellomy K; O'Neill K; Messinger Y; Johnson T; Chen CL
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1301-7. PubMed ID: 10565855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.
    Emu B; Fessel J; Schrader S; Kumar P; Richmond G; Win S; Weinheimer S; Marsolais C; Lewis S
    N Engl J Med; 2018 Aug; 379(7):645-654. PubMed ID: 30110589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.
    Japour AJ; Lertora JJ; Meehan PM; Erice A; Connor JD; Griffith BP; Clax PA; Holden-Wiltse J; Hussey S; Walesky M; Cooney E; Pollard R; Timpone J; McLaren C; Johanneson N; Wood K; Booth D; Bassiakos Y; Crumpacker CS
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Nov; 13(3):235-46. PubMed ID: 8898668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects.
    Cotte L; Dellamonica P; Raffi F; Yazdanpanah Y; Molina JM; Boué F; Urata Y; Chan HP; Zhu L; Chang I; Bertz R; Hanna GJ; Grasela DM; Hwang C
    J Acquir Immune Defic Syndr; 2013 Jul; 63(3):346-54. PubMed ID: 23771104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.
    Bratt G; Karlsson A; Leandersson AC; Albert J; Wahren B; Sandström E
    AIDS; 1998 Nov; 12(16):2193-202. PubMed ID: 9833861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.
    Wood R; Arasteh K; Stellbrink HJ; Teofilo E; Raffi F; Pollard RB; Eron J; Yeo J; Millard J; Wire MB; Naderer OJ
    Antimicrob Agents Chemother; 2004 Jan; 48(1):116-23. PubMed ID: 14693528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.
    Smith PF; Ogundele A; Forrest A; Wilton J; Salzwedel K; Doto J; Allaway GP; Martin DE
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3574-81. PubMed ID: 17638699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion.
    Nagashima KA; Thompson DA; Rosenfield SI; Maddon PJ; Dragic T; Olson WC
    J Infect Dis; 2001 Apr; 183(7):1121-5. PubMed ID: 11237840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.
    Schapiro JM; Winters MA; Stewart F; Efron B; Norris J; Kozal MJ; Merigan TC
    Ann Intern Med; 1996 Jun; 124(12):1039-50. PubMed ID: 8633817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex.
    Collier AC; Coombs RW; Katzenstein D; Holodniy M; Gibson J; Mordenti J; Izu AE; Duliege AM; Ammann AJ; Merigan T
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Oct; 10(2):150-6. PubMed ID: 7552478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.
    Funk MB; Notheis G; Schuster T; Elanjkal Z; von Hentig N; Stürmer M; Linde R; Dunsch D; Königs C; Wintergerst U; Kreuz W
    Eur J Med Res; 2005 Dec; 10(12):503-8. PubMed ID: 16356864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.
    Min S; Sloan L; DeJesus E; Hawkins T; McCurdy L; Song I; Stroder R; Chen S; Underwood M; Fujiwara T; Piscitelli S; Lalezari J
    AIDS; 2011 Sep; 25(14):1737-45. PubMed ID: 21716073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.